Gao Shenqiang

GaoSheng Biopharma is a China-based biotechnology company specializing in the discovery and development of next-generation small molecule therapeutics, with a primary focus on molecular glues and PROTACs. Founded in 2021 by Dr. Gao Shenqiang, a prominent figure in the targeted protein degradation (TPD) field and co-founder of Cullgen, the company utilizes its proprietary G-Glue platform to address "undruggable" protein targets. The platform integrates structural biology and computational modeling to identify novel E3 ligase ligands that can induce the degradation of disease-relevant proteins. GaoSheng's current pipeline is centered on high-value targets in oncology and immunology, aiming to develop oral therapies for complex conditions. Headquartered in Suzhou's BioBAY, the company has attracted significant investment from leading venture capital firms like Legend Capital.